YourEra Health research and fine print
YourEra presents a consumer telehealth platform rather than a single medical practice or pharmacy. Its terms separate YourEra from the Medical Groups, Providers, Pharmacies, and Labs that may deliver care or fulfillment. The names of those clinical and dispensing entities are not published before intake.
Legal identity is not consistent across current pages. The terms say YourEra, Inc. and its subsidiaries own and operate the platform. The privacy policy names Your Era Management, LLC, and the refund policy says that entity is invoiced by the pharmacy. Their exact relationship is not explained.
The company says practicing physicians in Covington, Louisiana founded the service and that board-certified physicians lead clinical decisions. No founder names, medical-group identities, individual clinician credentials, or patient-assignment method are provided on the reviewed pages, so those general claims are not converted into specific attribution.
Only compounded semaglutide and compounded tirzepatide receive normalized treatment cards. Both are identified as weekly subcutaneous injections. Marketing program names, billing terms, and dose schedules do not create additional therapies.
The GLP-1 pages say a clinician titrates treatment and the price stays the same at every dose. They do not disclose the complete formulation, salt form, additives, concentration, fill volume, number of doses per shipment, beyond-use date, or assigned pharmacy. Those gaps keep the offers outside like-for-like medication ranking.
NAD+ is advertised from $249 per month with a personalized self-administered protocol. The page does not establish injection, nasal, oral, or another route, and does not publish quantity or strength. It remains editorial-only rather than being forced into an NAD+ card.
Microdosing Protocols are advertised from $179 per month for mood, focus, and momentum, but the page never names the substance, active ingredient, route, or dosage form. This review does not infer a GLP-1 product from a separate educational article and does not treat the program as a therapy.
YourEra Optimum is labeled coming soon. Its proposed features include coaching, training, nutrition support, at-home testing, wearables integration, and monitoring. A future add-on is not counted as a current treatment or included benefit.
The full standard price tables remain accessible on a first-party purchase surface. Semaglutide is $594 every six months, $459 every 12 weeks, or $219 monthly. Tirzepatide is $1,194 every six months, $799 every 12 weeks, or $299 monthly.
The compact semaglutide figure averages effective rates of $99, $153, and $219, producing Avg. $157/mo. Tirzepatide's effective rates are $199, $266.33, and $299; the arithmetic mean is $254.78 and is displayed as Avg. $255/mo. The 12-week terms are treated as three months.
A newer promotional page automatically applies 20% to the six-month term, producing $79.20 per month for semaglutide and $159.20 for tirzepatide. The main catalog rounds those figures to $79 and $159. The promotion has no public expiry or affiliate-compatibility terms, so it is not averaged or attached beneath the CTA.
YourEra says the plan price includes the provider evaluation, prescription and medication if approved, injection supplies, dose adjustments, ongoing messaging, and shipping. The terms describe a single total that allocates service, pharmacy, and medical-group charges behind the scenes. Taxes or checkout-disclosed charges may still apply.
The homepage says there are no long-term contracts and that patients can pause or cancel at any time. The promotional page explicitly calls its $79.20 semaglutide rate a six-month commitment. The commitment disclosure controls the buying decision for that option.
A still-live purchase page says a card is charged only after a licensed provider approves a prescription and that a declined patient is not charged. Because the current intake now runs on another host, the same charging rule should be reconfirmed before relying on it.
Subscriptions renew automatically. The terms allow the first renewal to be charged early and later shipments to be charged or sent up to two days early for operational reasons. Cancellation must be requested through the account or help center at least two days before renewal and becomes effective after the current subscription period.
Refund eligibility ends early in fulfillment. A full refund may be requested only while the order has not begun pharmacy processing. Once preparation, compounding, or dispensing starts, the refund policy denies a refund whether or not the shipment has left the pharmacy or reached the patient.
The terms also deny partial-period refunds except at YourEra's discretion. This means canceling a six-month plan does not publicly promise reimbursement for unused time. Patients should confirm the initial charge, renewal date, cancellation deadline, and remaining commitment before submitting payment.
This is cash-pay care. The terms say YourEra and its Medical Groups do not participate in Medicare or Medicaid for these services and will not submit federal-program claims. The site says HSA and FSA funds may be eligible, but the plan administrator controls reimbursement.
The advertised onboarding sequence starts with a roughly five-minute health intake. A licensed provider reviews the information, may connect with the patient, and may prescribe only if treatment is clinically appropriate. An approved order is sent to a licensed U.S. pharmacy and ongoing communication occurs through the portal.
Consultation modality is not stated consistently. The promotional page says no appointment is needed and implies asynchronous review. The telehealth consent is written around videoconferencing equipment and a remote consulting provider. A live video requirement may depend on the clinician or state and should be confirmed during intake.
YourEra says its clinician network covers all 50 states, but it also says specific treatment availability varies by state and the intake confirms eligibility. Network reach does not prove that every product, clinician, or pharmacy can serve every location.
Pharmacy disclosure is generic. The site repeatedly says state-licensed U.S. pharmacies, while the terms allow some prescriptions to be sent to a local pharmacy selected by the patient and paid separately. No named dispenser or patient-specific assignment is available before the clinical process.
The promotional page depicts intake today, a prescription within one day, shipment within another day, and arrival in one to two days. The terms say all delivery dates are estimates and are not guaranteed. No complete processing cutoff, carrier schedule, cold-chain specification, delay remedy, or damaged-shipment replacement window is public.
General support uses support@yourera.com, and members are directed to patient-portal messaging for care questions. The site uses unlimited and anytime language, while an older purchase surface lists 24/7 clinical chat. No public phone number, staffed schedule, response-time target, or proof of live 24-hour coverage was found.
The privacy policy covers identity, health, billing, device, usage, location, and behavioral information. It permits analytics and advertising technologies, combines data from different sources, and allows aggregated or de-identified information to be used for research or marketing and shared with third parties including advertisers and sponsors.
YourEra says it is not itself a HIPAA covered entity, although it may act as a business associate for a Lab, Pharmacy, or Medical Group in some circumstances. California access and deletion requests can be sent to support@yourera.com. The policy gives a purpose-based retention standard rather than a fixed deletion timetable.
The site displays a 4.8 member rating, says it is trusted by thousands, and presents self-reported weight outcomes. No sample size, collection method, denominator, external audit, or linked dataset is provided. These claims are attributed to YourEra and are not imported as an AllyRx user rating.
YourEra displays a LegitScript Certified claim. The official domain checker did not return a readable verification result without its challenge during research, so the claim remains provider-presented rather than independently confirmed.
YourEra correctly states that its compounded semaglutide and tirzepatide are not the brand-name products and are not FDA approved. FDA guidance says compounded drugs do not receive premarket review for safety, effectiveness, or quality and warns telehealth companies against implying that compounds are approved generics or the same as approved products.
The terms impose confidential individual arbitration unless a timely opt-out is submitted, waive class proceedings and jury trial, require most claims within one year, cap YourEra's liability at $1,000 where enforceable, and apply Delaware law. These provisions do not describe clinical quality, but they are meaningful consumer contract terms.
The practical value is concentrated in price visibility and a simple remote workflow. The main uncertainties are whether the legacy standard plan table remains controlling on the new intake platform, which medical and pharmacy entities serve the patient, what exact compound is dispensed, and how quickly support and replacement issues are handled.
- Two exact GLP-1 ingredient-and-route cards avoid inflating the catalog with marketing programs.
- Three standard terms produce compact monthly averages while preserving every total and commitment.
- The automatic 20% six-month promotion is kept separate from durable comparison pricing.
- No-contract marketing conflicts with a disclosed six-month commitment and end-of-term cancellation.
- The refund right ends when pharmacy processing begins, even before shipment.
- Licensed clinicians and pharmacies are promised, but none is named for an individual patient before intake.
- The 1-to-2-day delivery sequence is an estimate without a documented replacement service level.
- Provider ratings, outcome figures, and certification remain provider-presented claims.